Arcus Biosciences, Inc.
New York Stock ExchangeTotal Valuation
Arcus Biosciences, Inc. carries a market capitalization of 3.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.05B |
| Enterprise Value | 1.76B |
Share Statistics
Arcus Biosciences, Inc. currently has 125.50M shares outstanding.
| Shares Outstanding | 125.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 10.45, and the price-to-book ratio stands at 4.70.
| PE Ratio | N/A |
| PS Ratio | 10.45 |
| PB Ratio | 4.70 |
| P/TBV Ratio | 4.70 |
| P/FCF Ratio | -5.07 |
| P/OCF Ratio | -5.05 |
Enterprise Valuation
| EV / Sales | 7.44 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Arcus Biosciences, Inc. maintains a current ratio of 4.04, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.56, indicating elevated leverage, while an interest coverage ratio of -38.90 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.04 |
| Quick Ratio | 3.97 |
| Debt / Equity | 21.56 |
| Debt / EBITDA | -0.29 |
| Interest Coverage | -38.90 |
Financial Efficiency
| Return on Equity (ROE) | -69.89 |
| Return on Assets (ROA) | -34.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Arcus Biosciences, Inc.'s stock has gained approximately 268.9781% over the past 52 weeks. The 50-day moving average sits at 25.40, while the 200-day moving average is 21.76.
| Beta (5Y) | N/A |
| 52-Week Price Change | 268.9781% |
| 50-Day Moving Average | 25.40 |
| 200-Day Moving Average | 21.76 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Arcus Biosciences, Inc. generated 236.00M in revenue and converted that into -369.00M in net income, yielding earnings per share of -3.23. EBITDA reached -389.00M, while operating income came in at -398.00M.
| Revenue | 236.00M |
| Gross Profit | N/A |
| Operating Income | -398.00M |
| Pretax Income | -369.00M |
| Net Income | -369.00M |
| EBITDA | -389.00M |
| EBIT | -398.00M |
| Earnings Per Share (EPS) | -3.23 |
Balance Sheet
Arcus Biosciences, Inc. holds 822.00M in cash and equivalents against 113.00M in total debt, resulting in a net debt position of -101.00M. Total book value stands at 525.00M, with working capital of 635.00M providing operational flexibility.
| Cash & Cash Equivalents | 822.00M |
| Total Debt | 113.00M |
| Net Debt | -101.00M |
| Equity (Book Value) | 525.00M |
| Book Value Per Share | 4.60 |
| Working Capital | 635.00M |
Cash Flow
Arcus Biosciences, Inc. produced -488.00M in operating cash flow over the past twelve months. After subtracting -1.00M in capital expenditures, free cash flow totaled -489.00M - equivalent to -4.28 per share.
| Operating Cash Flow | -488.00M |
| Capital Expenditures | -1.00M |
| Free Cash Flow | -489.00M |
| FCF Per Share | -4.28 |
Margins
Arcus Biosciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -168.64 and net profit margin of -156.36 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -168.64 |
| Pretax Margin | -156.36 |
| Profit Margin | -156.36 |
| EBITDA Margin | -164.83 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.16 |
| FCF Yield | -19.74 |
Scores
Arcus Biosciences, Inc. posts an Altman Z-Score of 0.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.55 |